Christopher Haqq Sells 1,604 Shares of Atara Biotherapeutics, Inc. (ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 1,604 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $13.36, for a total value of $21,429.44. Following the transaction, the executive vice president now directly owns 344,134 shares in the company, valued at approximately $4,597,630.24. The transaction was disclosed in a filing with the SEC, which is available at this link.

Christopher Haqq also recently made the following trade(s):

  • On Monday, October 16th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.35, for a total value of $86,100.00.
  • On Friday, September 15th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $15.30, for a total value of $91,800.00.

Atara Biotherapeutics, Inc. (ATRA) traded up $0.10 on Friday, reaching $14.60. The company had a trading volume of 165,671 shares, compared to its average volume of 233,711. Atara Biotherapeutics, Inc. has a 1 year low of $11.80 and a 1 year high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.05). analysts forecast that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/11/17/christopher-haqq-sells-1604-shares-of-atara-biotherapeutics-inc-atra-stock.html.

Several equities analysts recently issued reports on ATRA shares. Jefferies Group LLC reissued a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. Zacks Investment Research lowered Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Finally, Canaccord Genuity reissued a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $24.40.

A number of hedge funds have recently bought and sold shares of the business. Eagle Asset Management Inc. raised its position in Atara Biotherapeutics by 17.8% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock valued at $20,901,000 after purchasing an additional 225,367 shares in the last quarter. Neuberger Berman Group LLC raised its position in Atara Biotherapeutics by 15.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after purchasing an additional 147,061 shares in the last quarter. Vanguard Group Inc. raised its position in Atara Biotherapeutics by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after purchasing an additional 13,952 shares in the last quarter. Artal Group S.A. raised its position in Atara Biotherapeutics by 20.0% in the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock valued at $9,930,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Northern Trust Corp raised its position in Atara Biotherapeutics by 12.0% in the 2nd quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock valued at $4,183,000 after purchasing an additional 32,065 shares in the last quarter. 82.95% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply